Brief: Xintela Unit Engages Abzena For Production Of Targ9 And Targ10
June 2 (Reuters) - Xintela AB XINT.ST :
* TARGINTA ENGAGES ABZENA FOR THE PRODUCTION OF TARG9 AND
TARG10
* START OF PRODUCTION PROVIDES POTENTIAL TO START CLINICAL
TRIALS
IN CANCER PATIENTS IN H2 2024
Source text for Eikon: ID:nMFN1BNXWC
Further company coverage: XINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xintela AB
See all newsBrief: Xintela To Raise SEK 30 Mln Via Convertible Loan From Flerie Invest
Advisory: Alerts on Xintela's phase I/IIa XSTEM results withdrawn
Brief: Xintela Q1 2026 Loss Before Tax SEK 11.8 Mln
Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
Brief: Xintela Gets U.S. Patent For Xstem Treatment Of Difficult-To-Heal Wounds, Skin Defects